Hepion Pharmaceuticals, Inc. (HEPA) Stock Price & Analysis
Hepion Pharmaceuticals, Inc. (HEPA) rose 17.39% to USD 0.05 as of July 26, 2026 at 19:05 UTC, according to Nexqual real-time market data.
HEPA last closed at USD 0.05; the session ranged USD 0.04–0.06 on volume of 71,641 shares. Market capitalization is $1.57M, with a 52-week range of USD 0.03–0.11 (OQB). Source: Nexqual, July 26, 2026 at 19:05 UTC.
Key Statistics (as of July 26, 2026 at 19:05 UTC)
| Price | USD 0.05 |
|---|---|
| Change | ▲ 17.39% (up) |
| Previous Close | USD 0.05 |
| Open | USD 0.05 |
| Day Range | USD 0.04 – 0.06 |
| 52-Week Range | USD 0.03 – 0.11 |
| Volume | 71,641 shares |
| Market Cap | $1.57M |
| Exchange | OQB |
Technical Analysis (HEPA)
Nexqual's technical model rates HEPA "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 19:05 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.92 (neutral) |
| vs SMA50 | Below (USD 0.07) |
| MACD | -0 (negative) |
Analyst Ratings (HEPA)
Wall Street analysts rate HEPA "None", per Nexqual as of July 26, 2026 at 19:05 UTC.
| Consensus Rating | None |
|---|
Earnings (HEPA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-12-31 | USD -81.24 vs est -131.5 ▲ beat |
| 2023-09-30 | USD -137 vs est -156 ▲ beat |
| 2023-06-30 | USD -184 vs est -166.17 ▼ miss |
| 2023-03-31 | USD -174 vs est -180 ▲ beat |
Source: Nexqual, July 26, 2026 at 19:05 UTC.
Financials & Fundamentals (HEPA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -103.70% |
| Current Ratio | 3.68 |
| Total Cash | $2.60M |
| Total Debt | $0 |
| Free Cash Flow | $-227,412 |
Source: Nexqual, July 26, 2026 at 19:05 UTC.
Financial Health Score (HEPA)
Nexqual rates Hepion Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 19:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$2M |
| Efficiency | Critical — ROE -104%, ROA -45.4% |
Ownership (HEPA)
| Insider Ownership | +38.64% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 29.12M |
| Float | 20.37M |
| Short % of Float | +4.10% |
Source: Nexqual, July 26, 2026 at 19:05 UTC.
Leadership (HEPA)
Hepion Pharmaceuticals, Inc. is led by Vincent LoPriore (age 57), Executive Chairman, per Nexqual as of July 26, 2026 at 19:05 UTC.
| Executive Chairman | Vincent LoPriore (age 57) |
|---|---|
| Director of Investor Relations | Sharen Pyatetskaya |
From Hepion Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Although the FDA's Quality System Regulation (QSR) does not fully apply to investigational devices, the requirement for controls on design and development does apply.     Post-market Regulation   After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply.
- Our products may ultimately not be considered cost-effective, and adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to support a profitable operation or generate an appropriate return on our investment in product development.   The U.S. and foreign governments periodically propose and pass legislation designed to reduce the cost of healthcare and pharmaceutical products.
Partnerships
- In addition, we agreed to pay New Day up to $17.15 million upon achievement of certain regulatory, sales and reimbursement milestones.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CFOR | OpGen, Inc. | USD 18 | ▼ 10% |
| CLRB | Cellectar Biosciences, Inc. | USD 2.41 | ▼ 2.43% |
| MBRX | Moleculin Biotech, Inc. | USD 2.12 | ▲ 0.95% |
| TENX | Tenax Therapeutics, Inc. | USD 14.53 | ▼ 1.76% |
| PULM | Pulmatrix, Inc. | USD 1.65 | ▼ 2.37% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 19:05 UTC. This page is informational and not investment advice.